To assess Chinese physicians’ reports of chronic urticaria burden, support services, treatment patterns, barriers to treatment escalation, and use of traditional Chinese medicine.
Approach:
Design: Noninterventional, cross-sectional online survey conducted in simplified Chinese from August through October 2025.
Participants: A total of 265 China-based dermatologists and allergists who diagnosed and treated chronic urticaria and could prescribe guideline-recommended therapies, including biologics.
Key Findings:
Nineteen percent of surveyed physicians reported inadequately controlled chronic urticaria among their patients. Complete control was a priority for 93%, but physicians considered it achievable for 59% of patients.
Diagnosis was delayed by a mean of 1.3 years and involved consultations with four specialists.
Physicians reported mental health burden of 7.1/10 and sleep disturbance in 44% of patients; referrals to psychological support and sleep services were 25% and 23%, respectively.
The article reports conservative treatment escalation and a gap between physicians’ satisfaction with biologics and their use.
Interpretation:
The survey describes discrepancies between reported disease burden, treatment goals, and care delivery among participating Chinese physicians.
Limitations:
The cross-sectional, self-reported survey captures physician perspectives rather than patient-reported outcomes.
The provided article context does not include detailed sampling, response-rate, or full results information.
Conclusion:
The authors identify diagnostic delays, limited supportive-care referrals, and barriers to treatment escalation as areas requiring further attention in chronic urticaria management in China.
